Cargando…
Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer
Circulating tumor cells (CTCs) are a promising prognostic biomarker for cancers. However, the paucity of CTCs in peripheral blood in early-stage cancer is a major challenge. Our study aimed to investigate whether portal venous CTCs can be a biomarker for early recurrence and poor prognosis in pancre...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219704/ https://www.ncbi.nlm.nih.gov/pubmed/35740311 http://dx.doi.org/10.3390/biomedicines10061289 |
_version_ | 1784732181584674816 |
---|---|
author | Choi, Young Hoon Hong, Tae Ho Yoon, Seung Bae Lee, In Seok Lee, Myung Ah Choi, Ho Joong Choi, Moon Hyung Jung, Eun Sun |
author_facet | Choi, Young Hoon Hong, Tae Ho Yoon, Seung Bae Lee, In Seok Lee, Myung Ah Choi, Ho Joong Choi, Moon Hyung Jung, Eun Sun |
author_sort | Choi, Young Hoon |
collection | PubMed |
description | Circulating tumor cells (CTCs) are a promising prognostic biomarker for cancers. However, the paucity of CTCs in peripheral blood in early-stage cancer is a major challenge. Our study aimed to investigate whether portal venous CTCs can be a biomarker for early recurrence and poor prognosis in pancreatic cancer. Patients who underwent upfront curative surgery for resectable pancreatic cancer were consecutively enrolled in this prospective study. Intraoperatively, 7.5 mL of portal and peripheral blood was collected, and CTC detection and identification were performed using immunofluorescence staining. Peripheral blood CTC sampling was performed in 33 patients, of which portal vein CTC sampling was performed in 28. The median portal venous CTCs (2.5, interquartile ranges (IQR) 1–7.75) were significantly higher than the median peripheral venous CTCs (1, IQR 0–2, p < 0.001). Higher stage and regional lymph node metastasis were related with a larger number of CTCs (≥3) in portal venous blood. Patients with low portal venous CTCs (≤2) showed better overall (p = 0.002) and recurrence-free (p = 0.007) survival than those with high portal venous CTCs (≥3). If validated, portal CTCs can be used as a prognostic biomarker in patients with resectable pancreatic cancer. |
format | Online Article Text |
id | pubmed-9219704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92197042022-06-24 Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer Choi, Young Hoon Hong, Tae Ho Yoon, Seung Bae Lee, In Seok Lee, Myung Ah Choi, Ho Joong Choi, Moon Hyung Jung, Eun Sun Biomedicines Article Circulating tumor cells (CTCs) are a promising prognostic biomarker for cancers. However, the paucity of CTCs in peripheral blood in early-stage cancer is a major challenge. Our study aimed to investigate whether portal venous CTCs can be a biomarker for early recurrence and poor prognosis in pancreatic cancer. Patients who underwent upfront curative surgery for resectable pancreatic cancer were consecutively enrolled in this prospective study. Intraoperatively, 7.5 mL of portal and peripheral blood was collected, and CTC detection and identification were performed using immunofluorescence staining. Peripheral blood CTC sampling was performed in 33 patients, of which portal vein CTC sampling was performed in 28. The median portal venous CTCs (2.5, interquartile ranges (IQR) 1–7.75) were significantly higher than the median peripheral venous CTCs (1, IQR 0–2, p < 0.001). Higher stage and regional lymph node metastasis were related with a larger number of CTCs (≥3) in portal venous blood. Patients with low portal venous CTCs (≤2) showed better overall (p = 0.002) and recurrence-free (p = 0.007) survival than those with high portal venous CTCs (≥3). If validated, portal CTCs can be used as a prognostic biomarker in patients with resectable pancreatic cancer. MDPI 2022-05-31 /pmc/articles/PMC9219704/ /pubmed/35740311 http://dx.doi.org/10.3390/biomedicines10061289 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Choi, Young Hoon Hong, Tae Ho Yoon, Seung Bae Lee, In Seok Lee, Myung Ah Choi, Ho Joong Choi, Moon Hyung Jung, Eun Sun Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer |
title | Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer |
title_full | Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer |
title_fullStr | Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer |
title_full_unstemmed | Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer |
title_short | Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer |
title_sort | prognostic implications of portal venous circulating tumor cells in resectable pancreatic cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219704/ https://www.ncbi.nlm.nih.gov/pubmed/35740311 http://dx.doi.org/10.3390/biomedicines10061289 |
work_keys_str_mv | AT choiyounghoon prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer AT hongtaeho prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer AT yoonseungbae prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer AT leeinseok prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer AT leemyungah prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer AT choihojoong prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer AT choimoonhyung prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer AT jungeunsun prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer |